HC Wainwright reiterates Buy on Monte Rosa Therapeutics
Alpha Vantage · TradingView · · AI-summarised by FinFlash
HC Wainwright & Co. reiterated a Buy rating on Monte Rosa Therapeutics (GLUE) with a $25.00 price target, implying 138.1% upside from the recent closing price. The firm cited the company's clinical pipeline targeting immune-mediated diseases and metastatic prostate cancer, along with a probability-adjusted valuation of roughly $2.9 billion. All eight analysts covering the stock rate it Buy, with no Hold or Sell ratings.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.